Thank U for this amazing product
Nine trials were conducted in participants with overweight and/or obesity (Reference Ahmed Al-Naggar, Osman and Abdulghani23,Reference Alperet, Rebello and Khoo24,Reference Basu, Betts and Mulugeta26,Reference Cardoso, Salgado and Cesar28,Reference Kobayashi, Kawano and Ukawa31,Reference Mousavi, Vafa and Neyestani35,Reference Nabi, Sedighinejad and Haghighi37,Reference Ohnaka, Ikeda and Maki38,Reference Wedick, Brennan and Sun44) and nine in healthy participants (Reference Ahmed Al-Naggar, Osman and Abdulghani23,Reference Hochkogler, Schweiger and Rust29Reference Lecoultre, Carrel and Egli32,Reference Revuelta-Iniesta and Al-Dujaili39,Reference Superko, Bortz and Williams40,Reference van Dusseldorp, Katan and van Vliet42,Reference Wedick, Brennan and Sun44)
Yassine and Finch, 2020)
What is now needed are larger, prospective, randomized trials that can establish causality, characterize which women benefit most, identify the optimal timing and formulation of each therapy, and track outcomes across the full range of health domains this article has examined, metabolic, cardiovascular, cognitive, and functional
